A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing different doses of the medication RO7795081, compared to a placebo or semaglutide, in adults with type 2 diabetes to see how it affects blood sugar levels over 30 weeks.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 240 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-08 · est. completion 2026-11

Where 50 sites · Hungary, Poland, Spain, United States

What this study is testing ClinicalTrials.gov NCT07112872 ↗

Description as written by the study sponsor.

This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).

Treatments tested

RO7795081 also known as CT-996, RG6652 Drug

RO7795081 will be taken orally once daily (QD), according to the randomized dosing regimen, during the 30-week treatment period.
Semaglutide Drug

Semaglutide 14 mg will be taken orally QD, with up-titration as per label, during the 30-week treatment period.
Placebo Drug

Placebo will be taken orally QD during the 30-week treatment period.

Main thing measured	RO7795081 vs. Placebo: Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 30
Sponsor	Hoffmann-La Roche
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07112872 ↗